Literature DB >> 6505987

Penetration of cefaclor into bronchial mucosa.

G E Marlin, A J Nicholls, G R Funnell, R Bradbury.   

Abstract

Bronchial mucosal biopsy specimens were obtained during fibreoptic bronchoscopy in 30 patients receiving a new oral cephalosporin antibiotic, cefaclor (10 had 250 mg, 10 had 500 mg, and 10 had 1000 mg every eight hours). In 10 patients (from all dosage groups) cefaclor was undetectable in the bronchial mucosa but in every case the serum concentration was low, suggesting incomplete absorption. The mean (SD) bronchial mucosal concentration after 250 mg was 3.78 (1.77) micrograms/g (range 2.1-5.8 micrograms/g, n = 4), after 500 mg 4.43 (2.04) micrograms/g (range 2.0-7.1 micrograms/g, n = 8), and after 1000 mg 7.73 (2.76) micrograms/g (range 5.0-12.7 micrograms/g, n = 6). A significantly higher concentration in the bronchial mucosa was achieved with 1000 mg than with 250 mg (p less than 0.05) or 500 mg (p less than 0.025). These concentrations should be effective against Streptococcus pneumoniae, most strains being inhibited below 1.0 microgram/ml. The concentrations were within one dilution of the minimal inhibitory concentration for Haemophilus influenzae, most strains being inhibited below 4.0 micrograms/ml. Some strains of H influenzae will not be inhibited by the concentrations of cefaclor found in the bronchial mucosa, particularly those that are ampicillin resistant.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6505987      PMCID: PMC459929          DOI: 10.1136/thx.39.11.813

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Visualization of doxycycline in lung tissue and sinus secretions by fluorescent techniques.

Authors:  R H Liss; J C Norman
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

2.  Comparative pharmacology of cefaclor and cephalexin.

Authors:  O M Korzeniowski; W M Scheld; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

3.  Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.

Authors:  N J Bill; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

4.  In vitro studies with cefaclor, a new oral cephalosporin.

Authors:  C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

5.  Doxycycline concentrations in lung tissue, bronchial wall, and bronchial secretions.

Authors:  J Gartmann
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

6.  [Tobramycin Concentration in Human Lung Tissue (author's transl)].

Authors:  U Kroening; S Liebig; M Wundschock
Journal:  Infection       Date:  1978       Impact factor: 3.553

7.  Pharmacology of cefaclor in normal volunteers and patients with renal failure.

Authors:  J Santoro; B N Agarwal; R Martinelli; N Wenger; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  Cefaclor: in vitro spectrum of activity and beta-lactamase stability.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

9.  Treatment of acute bronchitis and pneumonia with cefaclor.

Authors:  K Mattson; O V Renkonen; L Laitinen; R Nikander-Hurme
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

10.  Pharmacological evaluation of cefaclor in volunteers.

Authors:  G R Hodges; C Liu; D R Hinthorn; J L Harms; D L Dworzack
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

View more
  9 in total

Review 1.  Pulmonary disposition of antimicrobial agents: methodological considerations.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 2.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

3.  Quantitative morphology and water distribution of bronchial biopsy samples.

Authors:  D R Baldwin; R Wise; J M Andrews; D Honeybourne
Journal:  Thorax       Date:  1992-07       Impact factor: 9.139

4.  Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

5.  Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens.

Authors:  D R Baldwin; J M Andrews; J P Ashby; R Wise; D Honeybourne
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

6.  Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa.

Authors:  D Honeybourne; J M Andrews; J P Ashby; R Lodwick; R Wise
Journal:  Thorax       Date:  1988-09       Impact factor: 9.139

7.  Antibiotic penetration into lung tissues.

Authors:  D Honeybourne
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

8.  Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens.

Authors:  I M Gould; G Harvey; D Golder; T M Reid; S J Watt; J A Friend; J S Legge; J G Douglas
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

9.  Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections.

Authors:  M Cazzola; M G Matera; C F Donner
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.